IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Holdings in Natera, Inc. $NTRA

IQ EQ FUND MANAGEMENT IRELAND Ltd increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 57.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,940 shares of the medical research company’s stock after buying an additional 9,424 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Natera were worth $4,176,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC raised its stake in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 96 shares in the last quarter. NewEdge Advisors LLC increased its holdings in Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares during the period. Focus Partners Wealth raised its position in Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in shares of Natera in the 2nd quarter valued at about $298,000. Finally, QRG Capital Management Inc. boosted its stake in shares of Natera by 28.5% in the 2nd quarter. QRG Capital Management Inc. now owns 6,961 shares of the medical research company’s stock valued at $1,176,000 after buying an additional 1,544 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,725 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total transaction of $1,090,388.25. Following the transaction, the chief executive officer directly owned 123,156 shares of the company’s stock, valued at approximately $28,420,710.12. This trade represents a 3.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Michael Burkes Brophy sold 6,939 shares of Natera stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the completion of the transaction, the chief financial officer owned 52,120 shares in the company, valued at approximately $11,874,499.60. This represents a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 455,899 shares of company stock worth $106,475,440 in the last 90 days. Company insiders own 5.63% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $197.08 on Friday. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36. The firm has a market capitalization of $27.26 billion, a P/E ratio of -86.06 and a beta of 1.64. The company’s fifty day moving average price is $234.15 and its 200 day moving average price is $195.75.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company’s quarterly revenue was up 34.7% on a year-over-year basis. During the same period last year, the firm earned ($0.26) EPS. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Regulatory/catalyst: Natera submitted a PMA to the FDA for Signatera CDx to detect minimal residual disease in bladder cancer after positive phase‑3 results — a potential pathway to a companion‑diagnostic revenue stream and better reimbursement/clinical adoption if approved. Natera files Signatera CDx PMA (Zacks)
• Neutral Sentiment: Routine insider trims: Several non‑executive insiders (e.g., Solomon Moshkevich, John Fesko) sold modest, single‑digit percentages of their positions; these look like routine liquidity actions but add incremental supply. InsiderTrades report on recent sales
• Negative Sentiment: Material CEO sale: CEO Steven Chapman sold 85,299 shares (~40% reduction) on Feb 2 for roughly $19.7M — a large, high‑visibility block that investors commonly view as a negative signal and that likely amplified downward pressure. CEO Form 4 (SEC)
• Negative Sentiment: Additional executive selling: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), further trimming insider ownership and reinforcing near‑term selling pressure. CEO additional Form 4 CFO Form 4 (SEC)

Analysts Set New Price Targets

Several brokerages recently weighed in on NTRA. Guggenheim raised their target price on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. BTIG Research raised their price objective on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. Wells Fargo & Company boosted their target price on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Piper Sandler increased their target price on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, Barclays raised their price target on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average target price of $249.20.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.